Scientists reported shrinkage in the brain due to new types of Alzheimer’s drugs, lecanemab and donanemab. The newspaper reports this Times Citing British researchers.
Lecanemab, developed by Japanese pharmaceutical company Eisai with its US partner Biogen, and donanemab from US Lilly have been called “revolutionary” drugs for Alzheimer’s disease because they help clear the brain of toxic amyloid protein, which is considered a hallmark of the disease. .
But David Thomas, head of policy at Alzheimer’s Research UK, says that although lecanemab and donanemab are moderately effective, they have very serious side effects, and the drugs shrink brain volume and can cause bleeding.
Meanwhile, it is recommended that the drugs be approved for sale and use in the UK from next week.
Before that researchers defined A special peptide that protects the brain from toxic proteins.
used to be a doctor in the name Early symptoms of Alzheimer’s disease.